Last Price
1.36
Today's Change
+0.01 (0.74%)
Day's Change
1.35 - 1.43
Trading Volume
433,498
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Erez Aminov Mr. Erez Aminov
Full Time Employees: 2 2
IPO Date: 2023-08-14 2023-08-14
CIK: 0001904286 0001904286
ISIN: US60458C1045 US60458C1045
CUSIP: 60458C104 60458C104
Beta: 6.73 6.73
Last Dividend: 0.00 0.00
Dcf Diff: 1.10 1.10
Dcf: 0.25 0.25
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.